File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.canlet.2004.11.021
- Scopus: eid_2-s2.0-19544385752
- PMID: 15922857
- WOS: WOS:000229850600005
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Upregulated Akt signaling adjacent to gastric cancers: Implications for screening and chemoprevention
Title | Upregulated Akt signaling adjacent to gastric cancers: Implications for screening and chemoprevention |
---|---|
Authors | |
Keywords | Carcinogenesis Chronic inflammation Preneoplasia |
Issue Date | 2005 |
Publisher | Elsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/canlet |
Citation | Cancer Letters, 2005, v. 225 n. 1, p. 53-59 How to Cite? |
Abstract | Most gastric adenocarcinomas arise as a longterm complication of Helicobacter pylori infection of the stomach, but the high prevalence of this infection limits the cost-effectiveness of antibiotic eradication as a cancer prevention strategy. Here we have used phosphorylation-specific antibodies against the Akt kinase consensus sequence to detect downstream substrates of this oncogenic signaling pathway in normal and malignant gastric tissues. In vitro studies confirm that phosphorylation of Akt and its substrates is inducible by epithelial mitogens such as epidermal growth factor (EGF), which is implicated in the pathogenesis of H. pylori gastritis. Control clinical studies confirm far stronger Akt substrate phosphorylation in primary human breast cancers than in matched adjacent normal breast tissues; unexpectedly, however, increased Akt signaling is apparent in both primary stomach cancers and adjacent normal gastric tissues. These findings raise the possibility of a preneoplastic field defect induced in morphologically normal tissues, and suggest that immunoassays of mucosal Akt activity could guide preventive surveillance and/or intervention in patients at risk of gastric cancer. Moreover, since recent reports confirm Akt inhibition by COX-2 inhibitors, these data support the chemopreventive efficacy of such drugs for at-risk individuals. © 2004 Elsevier Ireland Ltd. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/78574 |
ISSN | 2023 Impact Factor: 9.1 2023 SCImago Journal Rankings: 2.595 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kok, LA | en_HK |
dc.contributor.author | Diong, SL | en_HK |
dc.contributor.author | Wong, WK | en_HK |
dc.contributor.author | Epstein, RJ | en_HK |
dc.date.accessioned | 2010-09-06T07:44:23Z | - |
dc.date.available | 2010-09-06T07:44:23Z | - |
dc.date.issued | 2005 | en_HK |
dc.identifier.citation | Cancer Letters, 2005, v. 225 n. 1, p. 53-59 | en_HK |
dc.identifier.issn | 0304-3835 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/78574 | - |
dc.description.abstract | Most gastric adenocarcinomas arise as a longterm complication of Helicobacter pylori infection of the stomach, but the high prevalence of this infection limits the cost-effectiveness of antibiotic eradication as a cancer prevention strategy. Here we have used phosphorylation-specific antibodies against the Akt kinase consensus sequence to detect downstream substrates of this oncogenic signaling pathway in normal and malignant gastric tissues. In vitro studies confirm that phosphorylation of Akt and its substrates is inducible by epithelial mitogens such as epidermal growth factor (EGF), which is implicated in the pathogenesis of H. pylori gastritis. Control clinical studies confirm far stronger Akt substrate phosphorylation in primary human breast cancers than in matched adjacent normal breast tissues; unexpectedly, however, increased Akt signaling is apparent in both primary stomach cancers and adjacent normal gastric tissues. These findings raise the possibility of a preneoplastic field defect induced in morphologically normal tissues, and suggest that immunoassays of mucosal Akt activity could guide preventive surveillance and/or intervention in patients at risk of gastric cancer. Moreover, since recent reports confirm Akt inhibition by COX-2 inhibitors, these data support the chemopreventive efficacy of such drugs for at-risk individuals. © 2004 Elsevier Ireland Ltd. All rights reserved. | en_HK |
dc.language | eng | en_HK |
dc.publisher | Elsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/canlet | en_HK |
dc.relation.ispartof | Cancer Letters | en_HK |
dc.rights | Cancer Letters. Copyright © Elsevier Ireland Ltd. | en_HK |
dc.subject | Carcinogenesis | en_HK |
dc.subject | Chronic inflammation | en_HK |
dc.subject | Preneoplasia | en_HK |
dc.title | Upregulated Akt signaling adjacent to gastric cancers: Implications for screening and chemoprevention | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0304-3835&volume=225&issue=1&spage=53&epage=9&date=2005&atitle=Upregulated+Akt+signaling+adjacent+to+gastric+cancers:+implications+for+screening+and+chemoprevention. | en_HK |
dc.identifier.email | Epstein, RJ: repstein@hku.hk | en_HK |
dc.identifier.authority | Epstein, RJ=rp00501 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.canlet.2004.11.021 | en_HK |
dc.identifier.pmid | 15922857 | - |
dc.identifier.scopus | eid_2-s2.0-19544385752 | en_HK |
dc.identifier.hkuros | 122937 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-19544385752&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 225 | en_HK |
dc.identifier.issue | 1 | en_HK |
dc.identifier.spage | 53 | en_HK |
dc.identifier.epage | 59 | en_HK |
dc.identifier.isi | WOS:000229850600005 | - |
dc.publisher.place | Ireland | en_HK |
dc.identifier.scopusauthorid | Kok, LA=8509255600 | en_HK |
dc.identifier.scopusauthorid | Diong, SL=8509255200 | en_HK |
dc.identifier.scopusauthorid | Wong, WK=7403972446 | en_HK |
dc.identifier.scopusauthorid | Epstein, RJ=34975074500 | en_HK |
dc.identifier.issnl | 0304-3835 | - |